CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) indication : treatment of severe vernal keratoconjunctivitis in children from 4 years of age through adolescence
The CADTH Canadian Drug Expert Committee (CDEC) recommends that cyclosporine 0.1% be reimbursed for the treatment of severe vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence only if the following conditions are met : Conditions for Reimbursement, Initiation Cri...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2019, 2019
|
| Edition: | Version 1.1 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that cyclosporine 0.1% be reimbursed for the treatment of severe vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence only if the following conditions are met : Conditions for Reimbursement, Initiation Criteria 1. Between four and 18 years of age, inclusive. 2. Diagnosis of severe VKC defined as either: 2.1. grade 3 (severe) or 4 (very severe) on the Bonini scale, OR 2.2. grade 4 (marked) or 5 (severe) on the modified Oxford scale. 3. Severity of signs and symptoms of VKC should be documented by the treating physician at treatment initiation. 4. Patients previously treated with cyclosporine 0.1% but who discontinued treatment upon resolution of VKC signs and symptoms are eligible to reinitiate treatment if signs and symptoms of severe VKC recur and they meet the first and second initiation criteria |
|---|---|
| Physical Description: | 1 PDF file (8 pages) |